A disproportionality analysis of real-world adverse events associated with tirofiban from the FAERS database
Tirofiban, as a GP IIb/IIIa receptor antagonist, competitively inhibits the bridging of platelets via fibrin, which is the…
Philips FHI 2025 Cardiology Snapshot
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and…
Association between C-reactive protein-triglyceride glucose index and Future cardiovascular disease risk in a population with cardiovascular-Kidney-metabolic syndrome stage 0–3
This study is the first to investigate the relationship between the CTI and CVD risk among individuals with…
Phase 3 Trial Confirms Sarilumab Improves Polymyalgia Rheumatica Outcomes
Vibeke Strand, MD Credit: PRIME Education New phase 3 data supported the effectiveness of sarilumab 200 mg every…